231 related articles for article (PubMed ID: 34427990)
21. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
Stein EM
Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
[TBL] [Abstract][Full Text] [Related]
22. Enasidenib: First Global Approval.
Kim ES
Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
[TBL] [Abstract][Full Text] [Related]
23. Targeting the
Amaya ML; Pollyea DA
Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206
[TBL] [Abstract][Full Text] [Related]
24. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
[No Abstract] [Full Text] [Related]
25. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.
Montesinos P; Fathi AT; de Botton S; Stein EM; Zeidan AM; Zhu Y; Prebet T; Vigil CE; Bluemmert I; Yu X; DiNardo CD
Blood Adv; 2024 May; 8(10):2509-2519. PubMed ID: 38507688
[TBL] [Abstract][Full Text] [Related]
26. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
[TBL] [Abstract][Full Text] [Related]
27. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
de Botton S; Montesinos P; Schuh AC; Papayannidis C; Vyas P; Wei AH; Ommen H; Semochkin S; Kim HJ; Larson RA; Koprivnikar J; Frankfurt O; Thol F; Chromik J; Byrne J; Pigneux A; Thomas X; Salamero O; Vidriales MB; Doronin V; Döhner H; Fathi AT; Laille E; Yu X; Hasan M; Martin-Regueira P; DiNardo CD
Blood; 2023 Jan; 141(2):156-167. PubMed ID: 35714312
[TBL] [Abstract][Full Text] [Related]
28. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
[No Abstract] [Full Text] [Related]
30. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
31. Positive First Trial of Enasidenib for AML.
Cancer Discov; 2017 Aug; 7(8):OF1. PubMed ID: 28659444
[TBL] [Abstract][Full Text] [Related]
32. IDH2 inhibition in AML: Finally progress?
Stein EM
Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
[TBL] [Abstract][Full Text] [Related]
34. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
Wang L; Song J; Xiao X; Li D; Liu T; He X
J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
[TBL] [Abstract][Full Text] [Related]
35. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
[TBL] [Abstract][Full Text] [Related]
36. In brief: Two new drugs for AML.
Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
[No Abstract] [Full Text] [Related]
37. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.
Kats LM; Vervoort SJ; Cole R; Rogers AJ; Gregory GP; Vidacs E; Li J; Nagaraja R; Yen KE; Johnstone RW
Leukemia; 2017 Jun; 31(6):1466-1470. PubMed ID: 28280273
[No Abstract] [Full Text] [Related]
38.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract][Full Text] [Related]
39. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Abou Dalle I; DiNardo CD
Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
[TBL] [Abstract][Full Text] [Related]
40. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
